78 / 89
78
15.
Reece D, Song KW, Fu T, Roland B, Chang H, Horsman
DE, et al. Influence of cytogenetics in patients with
relapsed or refractory multiple myeloma treated with
lenalidomide plus dexamethasone: adverse effect of
deletion 17p13. Blood 2009;114:522-5.
16.
Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV,
Montalban MA, Fernandez-Redondo E, et al. Comparison
of immunofixation, serum free light chain, and
immunophenotyping for response evaluation and
prognostication in multiple myeloma. J Clin Oncol
2011;29:1627-33.
17.
Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM,
Larson D, Benson J, et al. Immunoglobulin free light chain
ratio is an independent risk factor for progression of
smoldering (asymptomatic) multiple myeloma. Blood
2008;111:785-9.
18.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-
Simón JA, Gutierrez NC, et al. Impact of genetic
abnormalities on survival after allogeneic hematopoietic
stem cell transplantation in multiple myeloma. Leukemia.
2008;22:1250-5.
19.
Durie BG, Salmon SE. A clinical staging system for
multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to
treatment, and survival. Cancer 1975;36:842-54.
20.
Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG,
Loughran TP Jr, et al. Beyond the CRAB symptoms: a
study of presenting clinical manifestations of multiple
myeloma. Clin Lymphoma Myeloma Leuk 2010;10:464-8.
21.
Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K,
Goldschmidt H, et al. Staging monoclonal plasma cell
disease: comparison of the Durie-Salmon and the Durie-
Salmon PLUS staging systems. Radiology 2010;257:195-
204.